Compare VII & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VII | PROF |
|---|---|---|
| Founded | N/A | N/A |
| Country | | Canada |
| Employees | N/A | 162 |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 307.8M | 248.8M |
| IPO Year | 2026 | 2017 |
| Metric | VII | PROF |
|---|---|---|
| Price | $9.82 | $6.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 42.3K | ★ 91.5K |
| Earning Date | N/A | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $16,098,000.00 |
| Revenue This Year | N/A | $92.40 |
| Revenue Next Year | N/A | $64.10 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 50.73 |
| 52 Week Low | $9.81 | $3.92 |
| 52 Week High | $9.89 | $8.95 |
| Indicator | VII | PROF |
|---|---|---|
| Relative Strength Index (RSI) | 40.52 | 46.63 |
| Support Level | $9.81 | $6.51 |
| Resistance Level | $9.89 | $6.94 |
| Average True Range (ATR) | 0.02 | 0.28 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 12.59 | 36.73 |
Viking Acquisition Corp II is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.